Literature DB >> 9443410

Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.

R Khanna1, P Busson, S R Burrows, C Raffoux, D J Moss, J M Nicholls, L Cooper.   

Abstract

Potentiation of the EBV-specific CTL response by immunization with CTL epitopes has been proposed as a logical approach for immune-targeting nasopharyngeal carcinoma (NPC) cells in vivo. This approach will undoubtedly be influenced by the ability of these malignant cells to endogenously process and present target epitopes on their cell surface for immune recognition by CTLs. Analysis of NPC cells in fresh tumor biopsies and long-term, established NPC tumors in nude mice revealed normal expression of the MHC-encoded putative peptide transporters TAP1 and TAP2, as well as the proteasome components LMP2 and LMP7, which have been shown previously to be essential components of the class I processing pathway. Moreover, these tumor cells also showed high levels of HLA class I alleles on the cell surface, suggesting that peptides are available for binding to nascent MHC molecules in the endoplasmic reticulum. Using a recombinant vaccinia virus to transiently express the EBV nuclear antigens, we studied the antigen-processing efficiency of NPC cells. Our findings demonstrate that, in contrast to cells from another EBV-associated malignancy, Burkitt's lymphoma, NPC cells display normal antigen-processing function and are efficiently recognized by HLA class I-restricted, virus-specific CTLs. These studies also provide a rationale for focusing on strategies designed to activate CTLs specific for EBV antigens that are expressed in NPC cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443410

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

Review 1.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

Review 2.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

3.  Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression.

Authors:  Corey Smith; Leone Beagley; Rajiv Khanna
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

4.  Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.

Authors:  N Kienzle; T B Sculley; L Poulsen; M Buck; S Cross; N Raab-Traub; R Khanna
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

Review 5.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Immune escape by Epstein-Barr virus associated malignancies.

Authors:  Christian Münz; Ann Moormann
Journal:  Semin Cancer Biol       Date:  2008-10-19       Impact factor: 15.707

7.  Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22.

Authors:  Raymond Wai-Ming Lung; Joanna Hung-Man Tong; Ying-Man Sung; Pak-Sing Leung; David Chi-Heng Ng; Shuk-Ling Chau; Anthony Wing-Hung Chan; Enders Kai-On Ng; Kwok-Wai Lo; Ka-Fai To
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

8.  Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.

Authors:  Edwin P Hui; Graham S Taylor; Hui Jia; Brigette B Y Ma; Stephen L Chan; Rosalie Ho; Wai-Lap Wong; Steven Wilson; Benjamin F Johnson; Ceri Edwards; Deborah D Stocken; Alan B Rickinson; Neil M Steven; Anthony T C Chan
Journal:  Cancer Res       Date:  2013-01-24       Impact factor: 12.701

9.  Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine.

Authors:  Viviana P Lutzky; Monika Corban; Lea Heslop; Leanne E Morrison; Pauline Crooks; David F Hall; William B Coman; Scott A Thomson; Denis J Moss
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  Gender-specific associations between MICA-STR and nasopharyngeal carcinoma in a southern Chinese Han population.

Authors:  Wei Tian; Xiao-Min Zeng; Li-Xin Li; He-Kun Jin; Qi-Zhi Luo; Fan Wang; Shi-Shi Guo; Ya Cao
Journal:  Immunogenetics       Date:  2006-03-18       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.